These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17634128)

  • 41. Simple and cost effective clinical methods for measuring neuromuscular fade responses with emphasis on "train of four" fade.
    Gyermek L
    J Clin Monit; 1997 Jan; 13(1):11-7. PubMed ID: 9058248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Block of postjunctional muscle-type acetylcholine receptors in vivo causes train-of-four fade in mice.
    Nagashima M; Sasakawa T; Schaller SJ; Martyn JA
    Br J Anaesth; 2015 Jul; 115(1):122-7. PubMed ID: 25835024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antagonism of non-depolarising neuromuscular block: current practice.
    Kopman AF; Eikermann M
    Anaesthesia; 2009 Mar; 64 Suppl 1():22-30. PubMed ID: 19222428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evolution of single twitch and train-of-four responses and of tetanic fade in relation to plasma concentrations of fazadinium in man.
    d'Hollander AA; Duvaldestin P; Delcroix C; Nevelsteen M; Desmonts JM
    Anesth Analg; 1982 Mar; 61(3):225-30. PubMed ID: 6121521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Onset of vecuronium-induced neuromuscular block after a long priming interval.
    Saitoh Y; Kaneda K; Murakawa M
    J Anesth; 2002; 16(2):102-7. PubMed ID: 14517658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro time course studies on train-of-four fade induced by hexamethonium, pancuronium and decamethonium in the rat hemidiaphragm.
    Gwee MC; Cheah LS
    Clin Exp Pharmacol Physiol; 1989 Dec; 16(12):897-903. PubMed ID: 2612066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Muscle relaxation in patients with Duchenne's muscular dystrophy. Use of vecuronium in two patients.
    Buzello W; Huttarsch H
    Br J Anaesth; 1988 Feb; 60(2):228-31. PubMed ID: 2894213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
    White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
    Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myasthenia gravis and myasthenic syndrome: simulation of twitch strength with or without therapy.
    Nigrovic V; Amann A; Bhatt S
    Muscle Nerve; 2005 Dec; 32(6):745-50. PubMed ID: 16094654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.
    Rex C; Wagner S; Spies C; Scholz J; Rietbergen H; Heeringa M; Wulf H
    Anesthesiology; 2009 Jul; 111(1):30-5. PubMed ID: 19512873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine.
    Lee C; Jahr JS; Candiotti KA; Warriner B; Zornow MH; Naguib M
    Anesthesiology; 2009 May; 110(5):1020-5. PubMed ID: 19387176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms underlying the vecuronium-induced tetanic fade in the isolated rat muscle.
    de Oliveira MJ; Oliveira AC
    Pharmacol Toxicol; 1999 Dec; 85(6):282-7. PubMed ID: 10628904
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical implications of sugammadex.
    Caldwell JE; Miller RD
    Anaesthesia; 2009 Mar; 64 Suppl 1():66-72. PubMed ID: 19222433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fade during recovery from vecuronium.
    Gampkin NT; Hood JR; Feldman SA
    Br J Anaesth; 1992 Aug; 69(2):226-7. PubMed ID: 1356396
    [No Abstract]   [Full Text] [Related]  

  • 55. Sugammadex in clinical practice.
    Mirakhur RK
    Anaesthesia; 2009 Mar; 64 Suppl 1():45-54. PubMed ID: 19222431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuromuscular transmission: new concepts and agents.
    de Boer HD
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
    de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
    Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Basic principles of neuromuscular transmission.
    Martyn JA; Fagerlund MJ; Eriksson LI
    Anaesthesia; 2009 Mar; 64 Suppl 1():1-9. PubMed ID: 19222426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An artificial neural network-based controller for the control of induced paralysis using vecuronium bromide.
    Kamangar FA; Behbehani K
    Ann Biomed Eng; 1997; 25(6):1040-51. PubMed ID: 9395049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between train-of-four ratio and first-twitch depression during neuromuscular blockade: a pharmacokinetic/dynamic explanation.
    Bartkowski RR; Epstein RH
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):335-46. PubMed ID: 2231323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.